An Evaluation of a Web-Based Decision Aid for Treatment Planning of Small Kidney Tumors: Pilot Randomized Controlled

Justin Fogarty1, Mutita Siriruchatanon1, Danil Makarov2,3

  • 1Department of Radiology, New York University Grossman School of Medicine, New York, NY, United States.

JMIR Research Protocols
|September 2, 2022
PubMed
Abstract

Insights

A new web-based decision aid (DA) helps patients with small kidney masses (SKMs) understand treatment options, potentially improving decision quality and favoring less invasive choices. This pilot study evaluates its impact on treatment selection.

Area of Science:

  • Urology
  • Decision Science
  • Health Informatics

Background:

  • Localized small kidney masses (SKMs) are often treated with surgery, despite limited survival benefit evidence.
  • Nonsurgical management is increasingly recognized for indolent SKMs.
  • Decision aids (DAs) enhance patient comprehension of treatment trade-offs and decision quality.

Purpose of the Study:

  • To evaluate a new web-based decision aid's impact on treatment selection (surgical vs. nonsurgical) for SKM patients.
  • To assess secondary outcomes including decisional conflict, satisfaction, and preference understanding.

Main Methods:

  • A three-phase approach involved developing a print DA, followed by an observational study, culminating in a pilot randomized controlled trial (RCT).
  • The pilot RCT (Phase 3) involved 50 adults with SKMs, comparing a web-based DA to an existing institutional website.
  • The web-based DA incorporates risk communication, preference elicitation, and a decision-analytic model considering patient factors.

Main Results:

  • Previous phases demonstrated the feasibility of print DA delivery and increased patient knowledge favoring nonsurgical options.
  • The pilot RCT (August 2022-January 2023) aims to establish feasibility and preliminarily evaluate decision outcomes.
  • Funding provided by the National Cancer Institute; recruitment began August 2022.

Conclusions:

  • A web-based DA has been developed to address educational needs for SKM treatment decisions, considering comorbidities and risks.
  • The pilot trial will assess the DA's potential for personalizing treatment choices and aiding patients in weighing surgical versus nonsurgical options.